Rhumbline Advisers Has $103,000 Stock Holdings in XBiotech Inc. (NASDAQ:XBIT)

Rhumbline Advisers raised its position in shares of XBiotech Inc. (NASDAQ:XBIT) by 2,568.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,094 shares of the biopharmaceutical company’s stock after purchasing an additional 19,341 shares during the period. Rhumbline Advisers owned approximately 0.07% of XBiotech worth $103,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in XBIT. Bank of New York Mellon Corp boosted its stake in shares of XBiotech by 102.9% during the second quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 49,863 shares in the last quarter. Empowered Funds LLC raised its position in shares of XBiotech by 7.9% in the 1st quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company’s stock worth $523,000 after acquiring an additional 4,725 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of XBiotech by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company’s stock valued at $7,279,000 after purchasing an additional 13,804 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.

XBiotech Stock Performance

Shares of XBIT stock opened at $7.73 on Tuesday. The company has a market cap of $235.44 million, a P/E ratio of -7.58 and a beta of 1.41. XBiotech Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $9.96. The stock has a 50 day simple moving average of $6.67 and a two-hundred day simple moving average of $7.13.

XBiotech (NASDAQ:XBIT) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.